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(To the Editor: In a previous communication (1), we traced the
history of spending on cardiovascular disease (CVD) treatment,
prevention, and research since 1996. As we noted there, such
spending estimates naturally lead to the question of whether the
money has been well spent. To begin to address this question, we
extend our previous results to provide a preliminary indication of
the cost-effectiveness of these expenditures and to identify gaps in
the cost-effectiveness literature.
To accomplish this goal, we link the previously reported
spending data with data from the CEA (Cost-Effectiveness
Analysis) Registry maintained by Tufts Medical Center. The
Registry is a nationally and internationally known and respected
resource containing detailed, standardized information on more
than 2,800 published cost-effectiveness analyses evaluating a wide
range of medical and health interventions. Each paper catalogued
in the Registry estimates the cost-effectiveness as an intervention’s
incremental costs (expressed here in 2010 U.S. dollars) divided by
its health benefits quantified in terms of quality-adjusted life-years
(QALYs) (2). Low cost-effectiveness ratios are “favorable” because
they indicate that incremental QALYs can be accrued inexpen-
sively. An intervention is “cost-saving” if it reduces costs while
improving health. Poorly performing interventions can both in-
crease costs and make health worse. The combined dataset links
expenditures associated with treatment or prevention of each type
of CVD with cost-effectiveness information for many of the
interventions for treating or preventing the condition. In an
attempt to control for the variability in the quality of the cost data
in the studies extracted from the Registry, we have included in the
combined dataset only studies that treated the discounting of cost
and effectiveness properly.
Table 1 summarizes the expenditure data previously presented
in reference 1, including national expenditures for various years
and compound annual growth rates for these expenditures from
1996 through 2008. To these data we have appended: 1) the
number of Registry-catalogued CEA studies published between
2000 and early 2011; 2) the number of studies per billion dollars of
CVD Expenditures and Cost-Effectiveness Findings by Spending CategoryTable 1 CVD Expenditures and Cost-Effectiveness Findings by Spending
Expenditures by Year ($ Billions)
1996 2002 2008
Treatment $133.6 $166.6 $234
Heart conditions $81.0 $94.2 $137
Coronary heart disease $53.5 $55.2 $82
Congestive heart failure $12.3 $17.6 $24
Dysrhythmias $12.6 $16.4 $24
Cerebrovascular disease $22.9 $24.0 $38
Prevention $22.1 $43.3 $68
Hypertension $13.3 $24.0 $30
Hyperlipidemia $4.0 $11.5 $26
Total $155.7 $210.0 $302CEA  cost-effectiveness analysis; CVD  cardiovascular disease; QALY  quality-adjusted life year.spending; and 3) the median cost per QALY calculated for
interventions in each spending category. The first two of these
statistics provide a rough indication of the resources devoted to
studying the cost-effectiveness of interventions for each condition
and how that sum compares with medical expenditures for that
condition; the third statistic provides a rough indication of the
cost-effectiveness of the medical spending.
Figure 1 illustrates the distribution of cost-effectiveness ratios
or CVD preventive interventions and for CVD treatments. The
gure is similar to that presented by Cohen et al. for all conditions
3), but is updated and restricted to CVD interventions.
We make the following observations from these exhibits:
• Median values in the far right column of Table 1 and the
general shape of the bar chart in Figure 1 suggest that, in
general, preventive measures are slightly more cost-effective
than treatment interventions. For example, Table 1 suggests
that the median ratio across all treatment interventions is
nearly $6,000 per QALY greater (less favorable) than the
median ratio for prevention.
• Most interventions, whether for prevention or treatment, do
not save money; as Figure 1 indicates, just more than 15% of
interventions in either class are cost saving. (This is also true
of interventions addressing a broad range of conditions (3)).
• On the other hand, all median ratios in the table are less than
the $50,000 per QALY threshold sometimes suggested as a
conservative basis for classifying interventions as cost-effective—
that is, providing good value (4).
• However, the figure illustrates that 16% of preventive mea-
sures and 25% of treatments have cost-effectiveness values
exceeding $100,000 per QALY, which is the threshold
sometimes considered to be an upper bound on what is
considered good value. These results suggest that opportuni-
ties may exist to improve the cost-effectiveness of both
prevention and treatment of CVD by reallocating resources
gory
Annual
Growth
No. of CEA
Studies
Studies/$B
Spending
Median
$/QALY
4.8% 262 1.12 $22,625
4.5% 193 1.41 $27,517
3.7% 88 1.06 $22,113
6.0% 31 1.26 $49,637
5.6% 30 1.23 $48,183
4.3% 41 1.08 $12,427
9.9% 97 1.42 $16,866
7.2% 25 0.82 $5,754
17.1% 9 0.33 $31,614
5.7% 359 1.19 $20,555Cate
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November 13, 2012:2123–6away from less efficient measures and toward more efficient
measures.
• Table 1 suggests that hypertension prevention is highly cost-
effective in general, with a median value of $5,754 per QALY.
• Relative to the spending on prevention of hyperlipidemia,
relatively few cost-effectiveness studies exist (0.33 studies per
billion dollars of expenditures in this category), possibly suggest-
ing a need for further analysis of hyperlipidemia measures.
• With the exception of hyperlipidemia, the number of studies
pertaining to each spending category is roughly proportional
to spending levels, with values ranging from 0.82 to 1.42
studies per billion dollars of expenditures.
Linking category expenditures and cost-effectiveness informa-
ion produces a rough indication of where CVD spending appears
o be cost-effective and where additional study may be needed to
etter characterize cost-effectiveness. Our work continues toward
efining these linkages.
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